Displaying drugs 26 - 50 of 154 in total
PF-03758309
PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors.
Investigational
Matched Name: … PF-03758309 …
Matched Description: … PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors. …
Matched Salts name: … Pf 03758309 Hydrochloride …
Matched Description: … PF-03758309 has been used in trials studying the treatment of Advanced Solid Tumors. …
Matched Salts name: … Pf 03758309 Hydrochloride …
PF-477736
PF-00477736 has been used in trials studying the treatment of Neoplasms.
Investigational
Matched Name: … PF-477736 …
Matched Description: … PF-00477736 has been used in trials studying the treatment of Neoplasms. …
Matched Description: … PF-00477736 has been used in trials studying the treatment of Neoplasms. …
PF-04217903
PF-04217903 has been used in trials studying the treatment of Neoplasms.
Investigational
Matched Name: … PF-04217903 …
Matched Description: … PF-04217903 has been used in trials studying the treatment of Neoplasms. …
Matched Description: … PF-04217903 has been used in trials studying the treatment of Neoplasms. …
PF-03814735
PF-03814735 has been used in trials studying the treatment of Solid Tumors.
Investigational
Matched Name: … PF-03814735 …
Matched Description: … PF-03814735 has been used in trials studying the treatment of Solid Tumors. …
Matched Description: … PF-03814735 has been used in trials studying the treatment of Solid Tumors. …
PF-03187207
PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF-03187207 is expected to have an increased capacity to reduce high IOP. The development of abnormally high IOP, due to blockage...
Investigational
Matched Name: … PF-03187207 …
Matched Description: … PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of ... Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF- …
Matched Description: … PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of ... Based on the very promising preclinical results and on the well-known activities of nitric oxide, PF- …
PF-00489791
PF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic Nephropathies, Hypertension, Pulmonary, and Peripheral Vascular Disease.
Investigational
Matched Name: … PF-00489791 …
Matched Description: … PF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic …
Matched Description: … PF-00489791 has been used in trials studying the treatment of Hypertension, Raynaud's Disease, Diabetic …
PF-03715455
PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive, and Chronic Obstructive Pulmonary Disease (COPD).
Investigational
Matched Name: … PF-03715455 …
Matched Description: … PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive …
Matched Description: … PF-03715455 has been used in trials studying the treatment of Asthma, Pulmonary Disease, Chronic Obstructive …
PF-03382792
Pf 03382792 is under investigation in clinical trial NCT01045863 (To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers).
Investigational
Matched Name: … PF-03382792 …
Matched Description: … Pf 03382792 is under investigation in clinical trial NCT01045863 (To Evaluate Safety, Tolerability, Plasma …
Matched Description: … Pf 03382792 is under investigation in clinical trial NCT01045863 (To Evaluate Safety, Tolerability, Plasma …
PF-06459988
PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer).
Investigational
Matched Name: … PF-06459988 …
Matched Description: … PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal …
Matched Description: … PF-06459988 is under investigation in clinical trial NCT02297425 (A Study For Patients With EGFRm (Epidermal …
PF-232798
PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Investigational
Matched Synonyms: … PF-00232798 …
Matched Name: … PF-232798 …
Matched Description: … Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects). ... PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple …
Matched Name: … PF-232798 …
Matched Description: … Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects). ... PF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple …
PF-07304814
PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro), which is used by viruses like SARS-CoV-2 to assemble and multiply . Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its anti-viral effects . PF-07304814, developed by Pfizer, was first identified during the...
Investigational
Matched Name: … PF-07304814 …
Matched Description: … PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was ... PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) ... Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its …
Matched Description: … PF-07304814, developed by Pfizer, was first identified during the SARS outbreak in 2002-2003; it was ... PF-07304814 is a small molecule prodrug that targets the 3CLpro protease (Mpro) ... Once administered through intravenous infusion, the compound is cleaved into PF-00835231 to exert its …
PF-06305591
Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple Doses of PF-06305591).
Investigational
Matched Name: … PF-06305591 …
Matched Description: … Doses of PF-06305591). ... Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple …
Matched Description: … Doses of PF-06305591). ... Pf 06305591 is under investigation in clinical trial NCT01776619 (Safety and Tolerability Study of Multiple …
PF-04457845
PF-04457845 is under investigation in Fear Conditioning. PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence.
Investigational
Matched Name: … PF-04457845 …
Matched Description: … PF-04457845 is under investigation in Fear Conditioning. ... PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence. …
Matched Description: … PF-04457845 is under investigation in Fear Conditioning. ... PF-04457845 has been investigated for the treatment of Tourette Syndrome and Cannabis Dependence. …
PF-05180999
PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999).
Investigational
Matched Name: … PF-05180999 …
Matched Description: … of a Modified-Release Formulation of PF-05180999). ... PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability …
Matched Description: … of a Modified-Release Formulation of PF-05180999). ... PF-05180999 is under investigation in clinical trial NCT01530529 (A Study to Assess the Relative Bioavailability …
PF-06291874
PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus).
Investigational
Matched Name: … PF-06291874 …
Matched Description: … PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics ... And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus …
Matched Description: … PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics ... And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus …
PF-06260414
PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects).
Investigational
Matched Name: … PF-06260414 …
Matched Description: … PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability ... Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects …
Matched Description: … PF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability ... Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects …
PF-05230907
PF-05230907 is a recombinant activated Factor X variant.
Investigational
Matched Name: … PF-05230907 …
Matched Description: … PF-05230907 is a recombinant activated Factor X variant. …
Matched Description: … PF-05230907 is a recombinant activated Factor X variant. …
PF-4191834
PF-4191834 has been investigated for the basic science of Asthma.
Investigational
Matched Name: … PF-4191834 …
Matched Description: … PF-4191834 has been investigated for the basic science of Asthma. …
Matched Description: … PF-4191834 has been investigated for the basic science of Asthma. …
PF-00217830
PF-00217830 has been used in trials studying the treatment of Schizophrenia.
Investigational
Matched Name: … PF-00217830 …
Matched Description: … PF-00217830 has been used in trials studying the treatment of Schizophrenia. …
Matched Description: … PF-00217830 has been used in trials studying the treatment of Schizophrenia. …
PF-07799933
PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer.
Investigational
Matched Name: … PF-07799933 …
Matched Description: … PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer. …
Matched Description: … PF-07799933 is a BRAF class 2 inhibitor developed by Pfizer. …
PF-04991532
PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, and Glucose Metabolism Disorders.
Investigational
Matched Name: … PF-04991532 …
Matched Description: … PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes …
Matched Description: … PF-04991532 has been used in trials studying the basic science of Diabetes Mellitus, Type 2 Diabetes …
PF-03463275
PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments Associated With Schizophrenia.
Investigational
Matched Name: … PF-03463275 …
Matched Description: … PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments …
Matched Description: … PF-03463275 has been used in trials studying the treatment of Schizophrenia and Cognitive Impairments …
Displaying drugs 26 - 50 of 154 in total